PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.07%
Revenue growth of 9.07% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
12.51%
Gross profit growth of 12.51% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
23.80%
EBIT growth of 23.80% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
26.60%
Operating income growth of 26.60% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
30.23%
Net income growth of 30.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
30.16%
EPS growth of 30.16% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
30.16%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.44%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3653.82%
OCF growth of 3653.82% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest positive difference, which can compound over time.
509.88%
FCF growth of 509.88% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
30.68%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 8.07%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
30.68%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 8.07%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
30.68%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 7.21%. Joel Greenblatt might see a short-term competitive advantage at play.
34.12%
OCF/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.62% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
34.12%
5Y OCF/share growth exceeding 1.5x Medical - Pharmaceuticals median of 21.35%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
34.12%
3Y OCF/share growth of 34.12% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
47.18%
Net income/share CAGR 50-75% of Medical - Pharmaceuticals median. Guy Spier would see lagging competitiveness in core profitability.
47.18%
5Y net income/share CAGR near Medical - Pharmaceuticals median. Charlie Munger might see standard mid-cycle performance in a healthy sector.
47.18%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 29.22%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
48.51%
Equity/share CAGR of 48.51% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
48.51%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.51%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
48.51%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.51%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
16.67%
Dividend/share CAGR of 16.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
16.67%
5Y dividend/share CAGR of 16.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
16.67%
3Y dividend/share CAGR of 16.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
No Data
No Data available this quarter, please select a different quarter.
2.94%
Inventory growth of 2.94% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
11.00%
Asset growth of 11.00% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
6.15%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
21.53%
Debt growth of 21.53% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.